Navigation Links
Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Date:8/9/2011

nd additional benefit with continued treatment. We look forward to presenting detailed results at a scientific meeting later this year."

Lexicon Conference Call and Webcast:

Lexicon management will be discussing the results of this study in conjunction with the second quarter earnings conference call today at 1:00 p.m. Eastern Time.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 89449241.  A live webcast of the call can be accessed at www.lexpharma.com.  An archived version of the webcast will be available on Lexicon's corporate website through September 6, 2011.

About Telotristat Etiprate (LX1032)

Telotristat etiprate was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome, especially diarrhea and carcinoid heart disease.  Serotonin's breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition.  In preclinical studies, telotristat etiprate reduced peripheral serotonin in several different species without affecting serotonin levels in the brain.  In Phase 1 clinical studies, telotristat etiprate reduced serotonin levels and urinary 5-HIAA in healthy volunteers consistent with preclinical results.  Telotristat etiprate is being developed under Fast Track designation from the U.S. Food and Drug Administration and orphan drug designation from the European Medicines Agency. Telotristat etiprate is a member of a new class of oral drugs invented by Lexicon, the serotonin synthesis inhibitors, which are being developed in a spectrum of gastrointestinal indications.  Lexicon is also currently planning a Phase 2 trial of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... NEW YORK , May 4, 2015  FireflySci Inc., the newest member of the ... months after launch, they have turned the cuvette industry on its head by offering scientists amazing ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... (PRWEB) May 04, 2015 San ... cutting ceremony at their brand new, 13,700 square foot ... The new building will not only provide fertility treatment ... will also offer community and educational events to a ... facility is located next door to their current Carmel ...
(Date:5/4/2015)... New West Medicare is excited to announce they ... outpatient advanced imaging services for its members. Care to ... are provided the right test at the right time ... West Medicare’s physicians and hospitals, Care to Care will ... and provide an objective basis for informed evidence-based clinical ...
(Date:5/4/2015)... May 04, 2015 Dr. Richard Champagne, ... been chosen to receive the America’s Best Dentist Award, ... Champagne’s selection as a top dentist is a reflection ... continuing education and his compassion for his patients. , ... who exemplify excellence in their field. These nominees are ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
(Date:5/4/2015)... Food Cost Calculator ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... food costs. , The restaurant industry is a vital cornerstone ... estimated 1.8 trillion dollar impact on the US economy. But ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2
... HALL, N.C., EXTON, Pa. and SAN DIEGO, Nov. ... southeastern US,provider of oncology equipment sales and service, ... alliance with Radiology Oncology Systems, Inc.,(ROS), an oncology ... Acceletronics, Inc., a US provider of oncology equipment ...
... Charged with Illegally Distributing over 12 Million Narcotic ... United States,Attorney Matt M. Dummermuth announced today that ... distribute controlled substances through an,Internet pharmacy and with ... in an Indictment filed today in United States ...
... Calif., Nov. 8 InteKrin Therapeutics, Inc.,a privately-held ... commercialization of novel drugs for the treatment of,diabetes ... M.D. has joined the company as Chief Medical ... senior management team and will be,responsible for the ...
... NEW YORK, Nov. 8 Wolf Popper LLP has ... MDT ) and,certain of its officers and directors ... Minnesota, on behalf of investors who purchased,Medtronic common stock ... 15, 2007 (the "Class Period"). This is the first ...
... (Unaudited) ... For the three months ended For the six months ended ... 2007 2006 ... $3,069,762 $2,315,781 $7,940,405 $7,836,896, Gross profit ...
... for Continued Efforts on $1 Billion ... Life Sciences Legislation Future of Biotechnology Featured: RNA, Nanomedicine, ... 2007 Editor,s Note: Reporters can listening to company presentations at, http://massbio.org/events/mass_opps/press.php ... available on Friday on the ...
Cached Medicine News:Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 3Health News:Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT 2Health News:Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT 3Health News:MagStar Technologies, Inc. Announces Third Quarter 2007 Results 2Health News:MagStar Technologies, Inc. Announces Third Quarter 2007 Results 3Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 2Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 3Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 4
The Olympus full range of laparoscopes includes a range of diameters and directions of view -12 mm HDTV compatible model as well as a choice of 10 mm, 5 mm full screen and 3 mm....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
This chamber is designed to provide a large workspace and gloveless dexterity in closed environment industrial, research and development, quality control packaging applications. Atmospheres of nitrog...
Medicine Products: